Osimertinib Has Transformed Lung Cancer Care — But at What Cost to the Heart?
Muhammad Awidi, Hematology and Oncology Fellow at Roswell Park Cancer Center, shared on LinkedIn.
”Osimertinib has changed the landscape for EGFR-mutated lung cancer, but its long-term heart safety has remained uncertain.
In our latest paper, we found that patients treated with osimertinib had higher rates of cardiomyopathy, ischemic heart disease, and heart failure compared with earlier-generation EGFR inhibitors. As survival improves, our findings highlight the need for ongoing cardiovascular monitoring to help prevent late toxicities.
Grateful to my outstanding co-authors Zaid Muhanna, Muntaser Zyoud, and Ahmad Issa three talented medical students I had the privilege to mentor on this project.”
Read the full Abstract here.
Stay updated with Hemostasis Today.
-
Dec 19, 2025, 13:30PPTA Europe’s Holiday Message: Wishing Health, Rest, and Renewal for 2026
-
Dec 19, 2025, 13:22If You Were Reading a “Bible for Blood Donation Volunteers,” What’s the ONE Thing That Must Be in It?
-
Dec 19, 2025, 12:52Julia Owens: Stroke Remains One of the World’s Leading Causes of Death and Disability
-
Dec 19, 2025, 12:03Pradeep Natarajan: Our New Genetic Study of Aortic Stenosis in ~3M
-
Dec 19, 2025, 11:47ESO Blog: Anna Gardin on Stroke Risk in the Era of Climate Extremes
-
Dec 19, 2025, 10:51Sarah Elkourashy Presents Insights on Caplacizumab for TTP at ASH25
-
Dec 19, 2025, 10:08Camilla Lombardi Shares an EHC Nutrition Guide for People with Bleeding Disorders
-
Dec 19, 2025, 09:56Danny Hsu Shares The ”I-WISh” Study by Nichola Cooper on ITP
-
Dec 19, 2025, 09:39Paul Bolaji: A Landmark Achievement -The Historic 1st Nigerian Stroke Leaders’ Summit 2025